Alkaline Phosphatase

( DrugBank: Alkaline Phosphatase / KEGG DRUG: - )

4 diseases

ID	Disease name (Link within this page)	Number of trials
46	Malignant rheumatoid arthritis	2
93	Primary biliary cholangitis	7

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	3
172	Hypophosphatasia	24

46. Malignant rheumatoid arthritis

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01416493 (ClinicalTrials.gov)	May 2011	11/8/2011	Bovine Intestinal Alkaline Phosphatase (bIAP) Modulating Rheumatoid Arthritis	An OPEN LABEL Phase II Safety Study of Bovine Intestinal Alkaline Phosphatase(bIAP), an Inflammation ...	Acute Rheumatoid Arthritis	Drug: s.c. injections of bovine intestinal Alkaline Phosphatase	Alloksys Life Sciences B.V.	Aix Scientifics	Completed	18 Years	N/A	Both	6	Phase 1/Phase 2	United Kingdom
2	EUCTR2008-007346-63-GB (EUCTR)	05/04/2011	11/10/2010	Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase(bIAP), An Inflammatio ...	Reumap: An Open Label phase II study of Bovine Intestinal Alkaline Phosphatase(bIAP), An Inflammatio ...	Rheumatoid Arthritis	Product Name: bIAP Product Code: EC 3.1.3.1 INN or Proposed INN: bovine intesastinal alkaline phosphat ...	Alloksys Life Sciences B.V.	NULL	Not Recruiting			Female: yes Male: yes		Phase 2	United Kingdom

First Previous1Next Last

93. Primary biliary cholangitis

Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115

trials per page:

Showing 1 to 7 of 7 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR2000032053	2020-05-01	2020-04-19	Application value of ultrasonography combined with transient elastography for staging of hepatic fib ...	Application value of ultrasonography combined with transient elastography for staging of hepatic fib ...	primary biliary cholangitis	Gold Standard:Any two of the following items met: 1. increased biochemical indicators of cholestasis ...	You'an Hospital, Capital Medical University	NULL	Pending	18	70	Both	Target condition:100;Difficult condition:270	N/A	China
2	EUCTR2016-004599-23-IT (EUCTR)	26/02/2018	07/01/2021	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess theEfficacy and Safety of Or ...	Primary Biliary Cholangitis MedDRA version: 21.0;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831	GENKYOTEX SA	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 2	United States;Greece;Canada;Spain;Belgium;Israel;Germany;United Kingdom;Italy
3	EUCTR2016-004599-23-GR (EUCTR)	27/10/2017	06/07/2017	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of O ...	Primary Biliary Cholangitis MedDRA version: 20.0;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831 Other descriptive name: GKT137831	Genkyotex SA	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 2	United States;Canada;Greece;Belgium;Spain;Israel;Germany;Italy;United Kingdom
4	EUCTR2016-004599-23-DE (EUCTR)	19/09/2017	10/07/2017	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of O ...	Primary Biliary Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831 Other descriptive name: GKT137831	Genkyotex SA	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 2	United States;Greece;Canada;Belgium;Spain;Israel;Germany;Italy;United Kingdom
5	EUCTR2016-004599-23-BE (EUCTR)	10/08/2017	10/04/2017	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of O ...	Primary Biliary Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831 Other descriptive name: GKT137831	Genkyotex SA	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 2	United States;Greece;Canada;Spain;Belgium;Israel;Germany;Italy;United Kingdom
6	EUCTR2016-004599-23-ES (EUCTR)	26/07/2017	04/07/2017	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of O ...	Primary Biliary Cholangitis MedDRA version: 20.0;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831 Other descriptive name: GKT137831	Genkyotex SA	NULL	Not Recruiting			Female: yes Male: yes	102	Phase 2	United States;Greece;Canada;Belgium;Spain;Israel;Germany;Italy;United Kingdom
7	EUCTR2016-004599-23-GB (EUCTR)	30/06/2017	17/05/2017	A study assessing the efficacy and safety of GKT137831 in Patients with Primary Biliary Cholangitis ...	A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of O ...	Primary Biliary Cholangitis MedDRA version: 20.1;Level: LLT;Classification code 10036680;Term: Prima ...	Product Code: GKT137831 INN or Proposed INN: GKT137831 Other descriptive name: GKT137831	Genkyotex SA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	102	Phase 2	United States;Greece;Canada;Belgium;Spain;Israel;Germany;Italy;United Kingdom

First Previous1Next Last

97. Ulcerative colitis

Clinical trials : 2,630 / Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

trials per page:

Showing 1 to 3 of 3 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2006-000197-69-CZ (EUCTR)	30/05/2006	10/03/2006	A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Ca ...	A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Ca ...	Inflammatory Bowel Disease	Product Name: Bovine-Calf Alkaline Phosphatase (BIAP)	AM-Pharma B.V.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	24		Czech Republic;Italy
2	NCT00727324 (ClinicalTrials.gov)	May 2006	30/7/2008	Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatasein Patients With Moderate to Severe U ...	A Pilot, Open-label, Multi-center Clinical Trial to Investigate the Safety and Efficacy of Bovine-Ca ...	Ulcerative Colitis	Drug: bovine intestinal alkaline phosphatase (BIAP)	AM-Pharma	CRM Biometrics GmbH;Sintesi Research Srl;Vigilex BV	Completed	18 Years	N/A	Both	22	Phase 2	Czech Republic;Italy
3	EUCTR2006-000197-69-IT (EUCTR)	16/03/2006	05/06/2006	A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Ca ...	A pilot, open-label, multi-center clinical trial to investigate the safety and efficacy of Bovine-Ca ...	Inflammatory Blowel Disease MedDRA version: 6.1;Level: PT;Classification code 10009900	Product Name: Bovine-Calf Alkaline Phosphatase BIAP Product Code: BIAP	AM PHARMA B.V.	NULL	Not Recruiting			Female: yes Male: yes	24		Italy

First Previous1Next Last

172. Hypophosphatasia

Clinical trials : 34 / Drugs : 17 - (DrugBank : 4) / Drug target genes : 3 - Drug target pathways : 6

trials per page:

Showing 1 to 10 of 24 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02496689 (ClinicalTrials.gov)	May 17, 2016	8/7/2015	Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset H ...	An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (Human Recombinant Tissue-nons ...	Hypophosphatasia	Biological: asfotase alfa	Alexion Pharmaceuticals	NULL	Approved for marketing	N/A	N/A	All			United States;France
2	EUCTR2015-003131-35-DE (EUCTR)	19/04/2016	03/12/2015	A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotas ...	A Phase 2a Randomized, Multi-center, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotas ...	Hypophosphatasia is a rare inborn error of bone metabolism caused by inactivating mutations in the g ...	Trade Name: Strensiq Product Name: asfotase alfa INN or Proposed INN: ASFOTASE ALFA Other descriptive n ...	Alexion Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	36	Phase 2	United States;Germany
3	EUCTR2015-000809-39-FR (EUCTR)	04/02/2016	05/08/2015	Access Program for Asfotase Alfa	An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (human recombinant tissue-nons ...	Hypophosphatasia MedDRA version: 18.0;Level: PT;Classification code 10049933;Term: Hypophosphatasia; ...	Trade Name: Strensiq Product Name: Asfotas Alfa Product Code: ENB-0040 INN or Proposed INN: ASFOTASE AL ...	Alexion Pharma International Sàrl	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	France;Belgium;Spain;Russian Federation;Netherlands
4	NCT02531867 (ClinicalTrials.gov)	June 2015	11/8/2015	Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in ...	A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific ...	Hypophosphatasia	Biological: Asfotase Alfa	Alexion Pharmaceuticals	NULL	Completed	N/A	N/A	All	13	Phase 4	NULL
5	JPRN-UMIN000014816	2014/08/11	11/08/2014	A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue ...	A Multicenter study of the safety and efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue ...	hypophosphatasia	Drug: Asfotase Alfa (ALXN1215) Dose: 6mg/kg/week (divided 3 times a week)	HPP study group	Translational Research Informatics Center	Complete: follow-up complete	Not applicable	Not applicable	Male and Female	20	Not selected	Japan
6	NCT02456038 (ClinicalTrials.gov)	August 2014	26/3/2015	Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)	A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue ...	Hypophosphatasia	Drug: Asfotase Alfa (ALXN1215)	Translational Research Informatics Center, Kobe, Hyogo, Japan	Osaka University Graduate School of Medicine	Completed	N/A	N/A	Both	13	Phase 2	Japan
7	EUCTR2010-019850-42-GB (EUCTR)	05/09/2013	01/02/2013	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	Hypophosphatasia MedDRA version: 19.1;Level: PT;Classification code 10049933;Term: Hypophosphatasia; ...	Trade Name: Strensiq Product Name: Asfotase alfa INN or Proposed INN: Asfotase alfa Other descriptive n ...	Alexion Pharma GmbH	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 2	United States;Taiwan;Saudi Arabia;Spain;Turkey;Russian Federation;United Kingdom;Italy;France;Canada ...
8	EUCTR2010-019850-42-ES (EUCTR)	28/06/2013	09/04/2013	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	Hypophosphatasia MedDRA version: 14.1;Level: PT;Classification code 10049933;Term: Hypophosphatasia; ...	Product Name: Asfotase alfa Product Code: ENB-0040 INN or Proposed INN: Asfotase alfa Other descriptive ...	Alexion Pharma International Sàrl	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Saudi Arabia;Taiwan;Spain;Turkey;United Kingdom;Italy;France;Canada;Argentina;Australi ...
9	EUCTR2010-019850-42-IT (EUCTR)	09/05/2013	01/03/2013	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfo ...	Hypophosphatasia MedDRA version: 15.1;Level: PT;Classification code 10049933;Term: Hypophosphatasia; ...	Product Name: Asfotase alfa Product Code: ENB-0040 INN or Proposed INN: Asfotase alfa Other descriptive ...	Alexion Pharma International Sàrl	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United States;Saudi Arabia;Taiwan;Spain;Turkey;Italy;United Kingdom;France;Canada;Argentina;Australi ...
10	EUCTR2010-024013-31-DE (EUCTR)	30/06/2011	07/02/2011	A clinical study to evaluate the safety and preliminary efficacy of BPS804 in adults with hypophosph ...	An open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmaco ...	Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal miner ...	Product Name: BPS804 Product Code: BPS804 Other descriptive name: fully human IgG2 lambda monoclonal a ...	Novartis Pharma Services AG	NULL	Not Recruiting			Female: yes Male: yes	9		Germany

First Previous1 2 3Next Last